Expert Opinion on Investigational Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pharmacological agents for bone fracture healing: talking points from recent clinical trials
This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the 2020 PRISMA statement. In April 2023, the following databases were accessed: PubMed, Web of Science, Google Scholar, Embase. All the randomized clinical trials investigating pharmacological agents for bone fracture healing were accessed. No time constraint was set for the search. The search was restricted to RCTs. No additional filters were used in the database search. Data from 19 RCTs (4067 patients) were collected. 78% (3160 of 4067) were women. The mean length of the follow-up was 9.3 months (range, 1-26 mo...
Source: Expert Opinion on Investigational Drugs - September 23, 2023 Category: Drugs & Pharmacology Authors: Filippo Migliorini Federico Cocconi Gianluca Vecchio Luise Sch äefer Julian Koettnitz Nicola Maffulli Source Type: research

Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials
Expert Opin Investig Drugs. 2023 Sep 20. doi: 10.1080/13543784.2023.2259309. Online ahead of print.ABSTRACTINTRODUCTION: Supraventricular tachycardias (SVT) are a diverse group of commonly encountered arrhythmias arising at or above the atrioventricular (AV) node. Conventional anti-arrhythmic medications are restricted by extensive side-effect profiles and limited efficacy. Catheter ablation has emerged as a first-line therapy for many arrhythmias, but is not a suitable option for all patients. This has prompted the exploration of novel pharmacological approaches targeting specific molecular mechanisms of SVT.AREAS COVERED...
Source: Expert Opinion on Investigational Drugs - September 20, 2023 Category: Drugs & Pharmacology Authors: Bharat Narasimhan Kruti Gandhi Errol Moras Lingling Wu Akanibo Da Wariboko Wilbert Aronow Source Type: research

Preclinical prospects of investigational agents for hearing loss treatment
Expert Opin Investig Drugs. 2023 Sep 11:1-8. doi: 10.1080/13543784.2023.2253141. Online ahead of print.ABSTRACTINTRODUCTION: : Hearing loss has a high prevalence, with aging, noise exposure, ototoxic drug therapies, and genetic mutations being some of the leading causes of hearing loss. Health conditions such as cardiovascular disease and diabetes are associated with hearing loss, perhaps due to shared vascular pathology in the ear and in other tissues.AREAS COVERED: : Issues in the design of preclinical research preclude the ability to make comparisons regarding the relative efficacy of different drugs of interest for pos...
Source: Expert Opinion on Investigational Drugs - September 11, 2023 Category: Drugs & Pharmacology Authors: Colleen G Le Prell Source Type: research

Emerging experimental drugs in clinical trials for migraine: observations and key talking points
Expert Opin Investig Drugs. 2023 Sep 8:1-11. doi: 10.1080/13543784.2023.2254691. Online ahead of print.ABSTRACTINTRODUCTION: There have been significant advances in the treatment of migraine. In response to the clinical success of monoclonal antibodies targeting calcitonin gene-related peptide, there is interest in the clinical trial outcomes of alternative emerging drugs that act on novel targets associated with migraine pathophysiology. As approximately 50% of patients do not respond to CGRP therapies, there is significant value in future drug innovation. Emerging drugs in clinical trials for the treatment of migraine ai...
Source: Expert Opinion on Investigational Drugs - September 6, 2023 Category: Drugs & Pharmacology Authors: William David Wells-Gatnik Tiffany Yazmin Wences Chirino Fatma Nur Onan Dilara Onan Paolo Martelletti Source Type: research

Emerging experimental drugs in clinical trials for migraine: observations and key talking points
Expert Opin Investig Drugs. 2023 Sep 6. doi: 10.1080/13543784.2023.2254691. Online ahead of print.ABSTRACTINTRODUCTION: There have been significant advances in the treatment of migraine. In response to the clinical success of monoclonal antibodies targeting calcitonin gene-related peptide, there is interest in the clinical trial outcomes of alternative emerging drugs that act on novel targets associated with migraine pathophysiology. As approximately 50% of patients do not respond to CGRP therapies, there is significant value in future drug innovation. Emerging drugs in clinical trials for the treatment of migraine aim to ...
Source: Expert Opinion on Investigational Drugs - September 6, 2023 Category: Drugs & Pharmacology Authors: William David Wells-Gatnik Tiffany Yazmin Wences Chirino Fatma Nur Onan Dilara Onan Paolo Martelletti Source Type: research